Key result
Levodopa replacement linked to improved neuroleptic malignant syndrome until enteral feeding interferes with drug absorption.
Why the study?
Neuroleptic malignant syndrome is a serious complication of levodopa withdrawal in patients with Parkinson's disease, with limited detailed clinical descriptions in advanced cases.
Case Report (n=1)
Enteral feeding can interfere with levodopa absorption, potentially worsening neuroleptic malignant syndrome in patients with advanced Parkinson's disease.
May warrant monitoring levodopa absorption during enteral feeding in advanced parkinsonism; leaves open broader applicability.
Neuroleptic malignant syndrome is a serious complication of levodopa withdrawal in patients with Parkinson's disease. We report a patient with advanced parkinsonism who developed neuroleptic malignant syndrome in the setting of inadequate levodopa intake. His symptoms improved with levodopa replacement, but dramatically worsened when enteral feeding was begun due to interference with intestinal absorption of levodopa.
No takes yet. Share an insight, caveat, or question.
Steven J. Frucht (2001) conducted a case report in Advanced Parkinson's disease (n=1). Levodopa replacement and enteral feeding was evaluated on Clinical symptoms of neuroleptic malignant syndrome. A patient with advanced parkinsonism and neuroleptic malignant syndrome improved with levodopa replacement, but symptoms worsened when enteral feeding interfered with levodopa absorption.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: